IL-2 signaling pathway (WP49)
IL-2 is a multifunctional cytokine with pleiotropic effects on several cells of the immune system. IL-2 was originally discovered as a T cell growth factor, but it was also found to have actions related to B cell proliferation, and cytolytic activity of natural killer cells. IL-2 also activates lymphokine activated killer cells. In contrast to its proliferative effects, IL-2 also has potent activity in a process known as activation-induced cell death. More recently, IL-2 was shown to promote tolerance through its effects on regulatory T cell development. IL-2 clinically has anti-cancer effects as well as utility in supporting T cell numbers in HIV/AIDS. There are three classes of IL-2 receptors, binding IL-2 with low, intermediate, or high-affinity. The low affinity receptor (IL-2RÃŽÂ± alone) is not functional; signaling by IL-2 involves either the high affinity hetero-trimeric receptor containing IL-2RÃŽÂ±, IL-2RÃŽÂ² and the common cytokine receptor gamma chain (originally named IL-2RÃŽÂ³ and now generally denoted as ÃŽÂ³c) or the intermediate affinity heterodimeric receptor composed of IL-2RÃŽÂ² and ÃŽÂ³c. IL-2 stimulation induces the activation of the Janus family tyrosine kinases JAK1 and JAK3, which associate with IL-2RÃŽÂ² and ÃŽÂ³c, respectively. These kinases in turn phosphorylate IL-2RÃŽÂ² and induce tyrosine phosphorylation of STATs (signal transducers and activators of transcription) and various other downstream targets. The downstream signaling pathways activated by IL-2 also involves mitogen-activated protein kinase and phosphoinositide 3-kinase signaling modules, leading to both mitogenic and anti-apoptotic signals. Please access this pathway at [http://www.netpath.org/netslim/IL_2_pathway.html NetSlim] database. NetPath is a collaborative project between PandeyLab at Johns Hopkins University (http://pandeylab.igm.jhmi.edu) and the Institute of Bioinformatics (http://www.ibioinformatics.org). If you use this pathway, please cite the NetPath website until the pathway is published.
AuthorsAkhilesh Pandey , Kristina Hanspers , Martina Summer-Kutmon , Martijn Van Iersel , Alex Pico , NetPath , Christine Chichester , Friederike Ehrhart , Egon Willighagen , and Eric Weitz
Discuss this pathway
Check for ongoing discussions or start your own.
- DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient survival (2021).
- Investigating the Molecular Processes behind the Cell-Specific Toxicity Response to Titanium Dioxide Nanobelts (2021).
- Hematopoietic stem-cell senescence and myocardial repair - Coronary artery disease genotype/phenotype analysis of post-MI myocardial regeneration response induced by CABG/CD133+ bone marrow hematopoietic stem cell treatment in RCT PERFECT Phase 3 (2020).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Pathway Ontologyinterleukin-2 signaling pathway Interleukin mediated signaling pathway
- NetPath: a public resource of curated signal transduction pathways. Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GSS, Venugopal AK, et al. Genome Biol. 2010 Jan 12;11(1):R3. PubMed Europe PMC Scholia